The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
Age:18 to 75 years old, male or female;
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Tumor was located in the pancreas;
Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;
Patients who did not meet these inclusion criteria;
Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders;
The investigators think inappropriate.
Single group
Camrelizumab+chemotherapy
DrugChemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy: AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles. Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.
hypofractionated radiotherapy
RadiationHypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),
a.R0-resection rate
The tumor was completely removed during surgery, and the cutting margins were also negative when viewed microscopically
Surgical conversion rate
Tumors that were otherwise unresectable were transformed into surgically resectable tumors.
Tumor regression rate
Degree of tumor response to neoadjuvant therapy
Objective response rate (ORR)
It refers to the proportion of patients who achieve a prespecified reduction in tumor volume (CR/PR) and maintain the minimum time requirements according to accepted response evaluation criteria (e.g., RECIST in solid tumors, version 1.1).
Disease control rate (DCR)
It refers to the proportion of patients who achieve a prespecified reduction in tumor volume (CR/PR/SD) and maintain the minimum time requirements according to accepted response evaluation criteria (e.g., RECIST in solid tumors, version 1.1).
Click on the lead sponsor to view all of their trials.
